RLMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RLMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-24), Relmada Therapeutics's current share price is $3.11. Relmada Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $3.20. Relmada Therapeutics's Cyclically Adjusted PB Ratio for today is 0.97.
The historical rank and industry rank for Relmada Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, Relmada Therapeutics's highest Cyclically Adjusted PB Ratio was 2.25. The lowest was 0.00. And the median was 0.00.
RLMD's Cyclically Adjusted PB Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Relmada Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was $2.388. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.20 for the trailing ten years ended in Mar. 2024.
The historical data trend for Relmada Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 0.81 | 0.85 | 0.99 | 1.34 | 1.45 |
For the Biotechnology subindustry, Relmada Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Relmada Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 3.11 | / | 3.2 | |
= | 0.97 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relmada Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Relmada Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 2.388 | / | 131.7762 | * | 131.7762 | |
= | 2.388 |
Current CPI (Mar. 2024) = 131.7762.
Relmada Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | -9.452 | 100.428 | -12.402 |
201412 | 1.711 | 99.070 | 2.276 |
201503 | 0.928 | 99.621 | 1.228 |
201506 | 3.269 | 100.684 | 4.279 |
201509 | 5.025 | 100.392 | 6.596 |
201512 | 3.922 | 99.792 | 5.179 |
201603 | 3.396 | 100.470 | 4.454 |
201606 | 2.340 | 101.688 | 3.032 |
201609 | 1.852 | 101.861 | 2.396 |
201612 | 1.554 | 101.863 | 2.010 |
201703 | 0.931 | 102.862 | 1.193 |
201706 | 0.466 | 103.349 | 0.594 |
201709 | 0.467 | 104.136 | 0.591 |
201712 | 0.230 | 104.011 | 0.291 |
201803 | -0.738 | 105.290 | -0.924 |
201806 | -1.757 | 106.317 | -2.178 |
201809 | -2.786 | 106.507 | -3.447 |
201812 | 0.193 | 105.998 | 0.240 |
201903 | 0.061 | 107.251 | 0.075 |
201906 | 0.781 | 108.070 | 0.952 |
201909 | 0.601 | 108.329 | 0.731 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 7.574 | 108.902 | 9.165 |
202006 | 8.342 | 108.767 | 10.107 |
202009 | 7.549 | 109.815 | 9.059 |
202012 | 6.464 | 109.897 | 7.751 |
202103 | 5.442 | 111.754 | 6.417 |
202106 | 5.544 | 114.631 | 6.373 |
202109 | 4.153 | 115.734 | 4.729 |
202112 | 7.508 | 117.630 | 8.411 |
202203 | 7.156 | 121.301 | 7.774 |
202206 | 6.556 | 125.017 | 6.910 |
202209 | 5.808 | 125.227 | 6.112 |
202212 | 4.666 | 125.222 | 4.910 |
202303 | 4.169 | 127.348 | 4.314 |
202306 | 3.699 | 128.729 | 3.787 |
202309 | 3.347 | 129.860 | 3.396 |
202312 | 2.836 | 129.419 | 2.888 |
202403 | 2.388 | 131.776 | 2.388 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Relmada Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Cedric O'gorman | officer: Chief Medical Officer | C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
Fabiana Fedeli | director | C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134 |
Sergio Traversa | director, officer: Chief Executive Officer | 138 CANTERBURY LN, BLUE BELL PA 19422 |
Paul Edward Kelly | director | 300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022 |
Charles J Casamento | director | 99 BELBROOK WAY, ATHERTON CA 94027 |
Maged Shenouda | director | 305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011 |
Thomas Wessel | officer: EVP, Head of R&D | 15 SKYLINE DRIVE, HAWTHORNE NY 10532 |
Eric Thomas Schmidt | director | C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
John Glasspool | director | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Chuck Ence | officer: Chief Financial Officer | 3000 S. UNIVERSITY BLVD., DENVER CO 80210 |
Ottavio V. Vitolo | officer: Chief Medical Officer | 71 WESTLAND AVENUE, NEWTON MA 02465 |
Shreeram Agharkar | director | P.O BOX 2042, PRINCETON NJ 08543 |
Sandesh Seth | director | 300 E 93RD STREET, #20-B, NEW YORK NY 10128 |
Lisa Nolan | officer: Chief Business Officer | 36 ROCKLAND MILLS, ROCKLAND DE 19732 |
Eliseo Oreste Salinas | officer: President and CSO | 7707 GATEWAY BLVD, NEWARK CA 94560 |
From GuruFocus
By ACCESSWIRE ACCESSWIRE • 05-23-2023
By PRNewswire PRNewswire • 06-03-2023
By PRNewswire • 10-09-2023
By GuruFocus Research • 11-08-2023
By PRNewswire PRNewswire • 05-24-2023
By PRNewswire PRNewswire • 06-08-2023
By sperokesalga sperokesalga • 06-10-2023
By PRNewswire PRNewswire • 05-16-2023
By sperokesalga sperokesalga • 06-05-2023